You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海吉亞醫療(06078.HK)2020年淨利同比增加345.0%至1.77億元
格隆匯 03-29 21:15

格隆匯 3 月 29日丨海吉亞醫療(06078.HK)公吿,截至2020年12月31日止年度全年業績,集團收入同比增加29.1%至14.02億元。集團淨利潤同比增加345.0%至1.77億元。集團每股基盈利由截至2019年12月31日止年度的人民幣0.14元增加171.4%至截至2020年12月31日止年度的人民幣0.38元。董事會建議派發截至2020年12月31日止年度的末期股息每股人民幣0.12元(合共約人民幣74.2百萬元)。

集團始終堅持以腫瘤業務為核心的發展戰略,通過直營民營營利性醫院、與第三方醫院合作經營放療中心、管理集團持有舉辦人權益的民營非營利性醫院,不斷擴大集團的業務規模。

截至2020年12月31日,集團(i)擁有及經營7家民營營利性醫院;(ii)管理3家民營非營利性醫院;及(iii)向17家醫院合作伙伴就其放療中心提供服務。集團堅持把患者滿意放在首位,注重醫療服務品質的提升,持續加強精細化管理。與上年相比,集團就診患者數量持續增加,次均費用穩步提升,促使集團2020年整體收入強勁增長以及經營管理效率顯著提升。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account